These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25645601)

  • 1. Urological cancer: abiraterone treatment improves overall survival in patients with mCRPC.
    Sidaway P
    Nat Rev Clin Oncol; 2015 Mar; 12(3):128. PubMed ID: 25645601
    [No Abstract]   [Full Text] [Related]  

  • 2. Abiraterone's efficacy confirmed; time to aim higher.
    Madan R; Dahut WL
    Lancet Oncol; 2015 Feb; 16(2):119-21. PubMed ID: 25601338
    [No Abstract]   [Full Text] [Related]  

  • 3. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is dexamethasone a better partner for abiraterone than prednisolone?
    Dizdar O
    Oncologist; 2015 May; 20(5):e13. PubMed ID: 25888271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Auchus RJ; Yu MK; Nguyen S; Mundle SD
    Oncologist; 2014 Dec; 19(12):1231-40. PubMed ID: 25361624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In reply.
    Auchus RJ; Yu MK; Nguyen S; Mundle SD
    Oncologist; 2015 May; 20(5):e14. PubMed ID: 25888269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
    Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
    Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
    Ma H; Zhu G; Wan B; Wu PJ; Wang JY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 46(4):653-6. PubMed ID: 25131489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Abiraterone: Overall survival benefit and subsidiary issues].
    Vignot S
    Bull Cancer; 2015 Jun; 102(6):487-8. PubMed ID: 25976372
    [No Abstract]   [Full Text] [Related]  

  • 11. An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer.
    Bertaglia V; Tucci M; Vignani F; Buttigliero C; Aroasio E; Berruti A; Scagliotti GV; DI Maio M
    Minerva Urol Nefrol; 2017 Aug; 69(4):349-358. PubMed ID: 28008755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone-induced rhabdomyolysis: A case report.
    Moore DC; Moore A
    J Oncol Pharm Pract; 2017 Mar; 23(2):148-151. PubMed ID: 26637407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)].
    Miller K
    Aktuelle Urol; 2019 Dec; 50(6):625-628. PubMed ID: 30919390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.
    Gunduz S; Bozcuk H; Yıldız M; Goksu SS; Uysal M; Arslan D; Tatlı AM; Mutlu H; Coşkun HS; Ozdogan M
    Indian J Cancer; 2015; 52(4):658-60. PubMed ID: 26960509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
    Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
    Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.
    Francini E; Fiaschi AI; Petrioli R; Bianco V; Laera L; Francini F; Roviello G
    Anticancer Drugs; 2015 Sep; 26(8):910-1. PubMed ID: 26207428
    [No Abstract]   [Full Text] [Related]  

  • 18. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
    Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
    J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
    Davies RS; Smith C; Button MR; Tanguay J; Barber J; Palaniappan N; Staffurth J; Lester JF
    Anticancer Res; 2015 Oct; 35(10):5615-21. PubMed ID: 26408734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.